Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TVP-1012 1 mg in early Parkinson's disease without prior levodopa
jRCT2080222708Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing TVP-1012 1 mg with Placebo (2 arms). Started Jan 2015; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080222708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222708.